Constellation banks $22M for ambitious epigenetics play

Constellation Pharmaceuticals has bagged $22 million in a new venture round that will bankroll an aggressive startup biotech with ambitious plans to make a reputation for itself in the emerging field of epigenetics. Originally launched under the leadership of Third Rock Ventures' Mark Levin with additional funds from The Column Group, Venrock, and Altitude Life Science Ventures, Constellation's Series B was led by SR One, the high-profile venture arm of GlaxoSmithKline. And it brings their...